Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for QIAGEN N.V. (QGEN : NYSE)

• Company Description    QIAGEN N.V. is one of the world's leading providers of technologies and products for the separation, purification and handling of nucleic acids DNA/RNA. The company provides innovative technologies and products for pre-analytical sample preparation and molecular diagnostics solutions. It has developed a comprehensive portfolio of proprietary, consumable products, and automated solutions for sample collection. Qiagen has subsidiaries several other countries with good sales potential. Segment Details Consumables: These are typically sample preparation or test kits that contain all the necessary reagents and buffers, and a manual including protocols and relevant background information. Automated Instruments: These automate the use of Sample & Assay Technologies into efficient solutions for a broad range of laboratory needs. Customer Classes: QIAGEN focuses on 4 principal segments or customer classes for sample and assay technologies:? Molecular Diagnostics, Applied Testing, Pharma and Academia. Number of Employees: 5,765

• Price / Volume Information    Yesterday's Closing Price: $48.55 Daily Weekly Monthly 20 Day Moving Average: 1,191,920 shares Shares Outstanding: 222.29 (millions) Market Capitalization: $10,792.22 (millions) Beta: 0.68 52 Week High: $48.90 52 Week Low: $37.63 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 2.45% -1.39% 12 Week 19.26% 0.31% Year To Date 6.00% -0.73%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL HULSTERWEG 82 - PL VENLO,P7 5912 NLD ph: 31-77-355-6600 fax: 31-77-355-6658 john.gilardi@qiagen.com http://www.qiagen.com

• General Corporate Information    Officers Thierry Bernard - Chief Executive Officer Roland Sackers - Chief Financial Officer Toralf Haag - Supervisory Director Eva Pisa - Supervisory Director Metin Colpan - Supervisory Director Peer Information QIAGEN N.V. (CORR.) QIAGEN N.V. (RSPI) QIAGEN N.V. (CGXP) QIAGEN N.V. (BGEN) QIAGEN N.V. (GTBP) QIAGEN N.V. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: N72482206 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/05/25 Share - Related Items Shares Outstanding: 222.29 Most Recent Split Date: 1.00 (0.97:1) Beta: 0.68 Market Capitalization: $10,792.22 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.51% Current Fiscal Quarter EPS Consensus Estimate: $0.57 Indicated Annual Dividend: $0.25 Current Fiscal Year EPS Consensus Estimate: $2.34 Payout Ratio: 0.00 Number of Estimates in the Fiscal Year Consensus: 9.00 Change In Payout Ratio: 0.00 Estmated Long-Term EPS Growth Rate: 8.39% Last Dividend Paid: 07/02/2025 - $0.25 Next EPS Report Date: 08/05/25

• Fundamental Ratios P/E Current FY Estimate: 20.71 Trailing 12 Months: 21.00 PEG Ratio: 2.47 Price Ratios Price/Book: 3.17 Price/Cash Flow: 15.15 Price / Sales: 5.39 EPS Growth vs. Year Ago Period: 16.24% vs. Previous Quarter: -9.84% Sales Growth vs. Year Ago Period: 5.37% vs. Previous Quarter: -7.24% ROE 06/30/25 - - 03/31/25 - 14.61 12/31/24 - 13.92 ROA 06/30/25 - - 03/31/25 - 8.80 12/31/24 - 8.40 Current Ratio 06/30/25 - - 03/31/25 - 3.37 12/31/24 - 3.61 Quick Ratio 06/30/25 - - 03/31/25 - 2.83 12/31/24 - 3.09 Operating Margin 06/30/25 - - 03/31/25 - 25.36 12/31/24 - 24.80 Net Margin 06/30/25 - - 03/31/25 - 4.68 12/31/24 - 4.23 Pre-Tax Margin 06/30/25 - - 03/31/25 - 6.91 12/31/24 - 6.12 Book Value 06/30/25 - - 03/31/25 - 15.33 12/31/24 - 16.05 Inventory Turnover 06/30/25 - - 03/31/25 - 3.38 12/31/24 - 3.05 Debt-to-Equity 06/30/25 - - 03/31/25 - 0.40 12/31/24 - 0.38 Debt-to-Capital 06/30/25 - - 03/31/25 - 28.41 12/31/24 - 27.28

Powered by Zacks Investment Research ©